DA-1726: Mechanism, Trials, and What the Data Actually Shows
DA-1726 is a Phase 1 program from NeuroBo built around Oxyntomodulin (GLP-1/GCG). This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
NeuroBo
Mechanism
Oxyntomodulin (GLP-1/GCG)
Stage
Phase 1
Tracked in
Non-incretin mechanisms
Approval and timeline
Need the straight approval read on DA-1726?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View DA-1726 statusCompound facts for search and AI answers
What this DA-1726 tracking page answers
Compound
DA-1726 from NeuroBo
DA-1726 is tracked in the non-incretin mechanisms group.
Mechanism
Oxyntomodulin (GLP-1/GCG)
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
Phase 1
This program is in early human testing. Phase 1 and Phase 1b data can tell us whether the mechanism is plausible in people, but they usually do not settle the bigger questions around long-term efficacy, tolerability, or commercial viability.
Evidence read
No mature public weight-loss signal pinned yet
DA-1726 should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program is in early human testing. Phase 1 and Phase 1b data can tell us whether the mechanism is plausible in people, but they usually do not settle the bigger questions around long-term efficacy, tolerability, or commercial viability. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Clinical evidence snapshot
What the evidence can and cannot say about DA-1726
DA-1726 should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program is in early human testing. Phase 1 and Phase 1b data can tell us whether the mechanism is plausible in people, but they usually do not settle the bigger questions around long-term efficacy, tolerability, or commercial viability. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Decision path
Is DA-1726 available now or watchlist only?
DA-1726 should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- DA-1726
- Developer
- NeuroBo
- Stage
- Phase 1
- Mechanism
- Non-incretin mechanisms
Step 1
Read the stage first
This program is in early human testing. Phase 1 and Phase 1b data can tell us whether the mechanism is plausible in people, but they usually do not settle the bigger questions around long-term efficacy, tolerability, or commercial viability.
Check statusStep 2
Separate evidence from access
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is DA-1726?
DA-1726 is a phase 1 obesity or metabolic program from NeuroBo built around Oxyntomodulin (GLP-1/GCG).
Is DA-1726 approved?
No. DA-1726 is still a Phase 1 asset. It is an early obesity story with mechanism intrigue, not a near-term launch candidate.
When could it matter?
2029 or later if the program matures successfully.
What DA-1726 is
DA-1726 is part of the non-incretin mechanisms cluster in the FormBlends obesity-pipeline map. We track it because NeuroBo is using Oxyntomodulin (GLP-1/GCG) as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program is in early human testing. Phase 1 and Phase 1b data can tell us whether the mechanism is plausible in people, but they usually do not settle the bigger questions around long-term efficacy, tolerability, or commercial viability.
Non-incretin obesity programs matter because they are not just trying to be another GLP-1. They represent alternative bets on muscle preservation, central appetite signaling, energy expenditure, and rare-disease pathways that could reshape the category if they work.
What FormBlends is watching next
For DA-1726, the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
More non-incretin mechanisms on FormBlends
Frequently asked questions
What is DA-1726?
DA-1726 is a Phase 1 obesity or metabolic compound from NeuroBo. FormBlends tracks it in the non-incretin mechanisms group and follows it for trial progress, regulatory movement, and competitive impact.
How does DA-1726 work?
DA-1726 is being tracked as a Oxyntomodulin (GLP-1/GCG) program. That mechanism is the main reason it sits inside the non-incretin mechanisms bucket of the 2026 obesity pipeline.
Is DA-1726 available now?
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Why is FormBlends tracking DA-1726?
Non-incretin obesity programs matter because they are not just trying to be another GLP-1. They represent alternative bets on muscle preservation, central appetite signaling, energy expenditure, and rare-disease pathways that could reshape the category if they work.